Cresco Labs Inc. (OTCMKTS:CRLBF) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Cresco Labs Inc. (OTCMKTS:CRLBF) have been assigned an average rating of “Moderate Buy” from the eight brokerages that are presently covering the stock, Marketbeat Ratings reports. Four research analysts have rated the stock with a hold recommendation, two have issued a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $2.50.

A number of equities research analysts have weighed in on the company. Atb Cap Markets lowered Cresco Labs from a “strong-buy” rating to a “hold” rating in a research note on Monday, December 9th. Roth Capital raised shares of Cresco Labs to a “strong-buy” rating in a research report on Sunday, November 10th. Finally, Cormark cut shares of Cresco Labs from a “moderate buy” rating to a “hold” rating in a report on Monday, November 11th.

Cresco Labs Trading Down 0.6 %

Shares of CRLBF stock opened at $0.93 on Friday. Cresco Labs has a 1-year low of $0.78 and a 1-year high of $2.65. The firm’s 50-day simple moving average is $0.97 and its 200-day simple moving average is $1.37. The firm has a market cap of $453.97 million, a P/E ratio of -4.65 and a beta of 1.79. The company has a debt-to-equity ratio of 1.80, a current ratio of 1.97 and a quick ratio of 1.39.

About Cresco Labs

Cresco Labs Inc, together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand.